Borregaard's operating revenues reached NOK 1,615 million (NOK 1,419 million)(2)
in the 1(st) quarter of 2022. EBITDA was NOK 400 million (NOK 302 million). The
result increased in all business areas. The net currency impact on EBITDA was
positive compared with the 1(st) quarter of 2021.
Higher sales prices and a strong product mix, partly offset by increased energy
and freight costs, were the main reasons for the EBITDA improvement in
BioSolutions. Higher sales prices more than compensated for lower deliveries and
increased energy and raw material costs in BioMaterials. For Fine Chemicals, the
EBITDA increase was due to higher deliveries and increased sales prices, partly
offset by increased costs.
Profit before tax was NOK 277 million (NOK 176 million). Earnings per share was
NOK 2.18 (NOK 1.47).
- We are pleased to deliver improved results in all business areas, where price
increases and improved product mix more than compensated for cost increases,
says President and CEO Per A. Sørlie.
Contacts:
Chief Financial Officer, Per Bjarne Lyngstad, +47 952 44 515
Director Communication, Tone Horvei Bredal, +47 924 67 711
1. Operating profit before depreciation, amortisation and other income and
expenses
2. Figures in parentheses are for the corresponding period in the preceding year
This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act.